An investigation for investors in NASDAQ:AEGR shares concerning potential breaches of fiduciary duties by certain Aegerion Pharmaceuticals directors was announced.
Investors who are current long term investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm for investors in NASDAQ:AEGR stocks follows a lawsuit filed against Cambridge, MA based Aegerion Pharmaceuticals over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:AEGR stocks, concerns whether certain Aegerion Pharmaceuticals directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that Aegerion Pharmaceuticals, Inc. violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Aegerion Pharmaceuticals Inc’s products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia.
The plaintiff claims that the defendants made allegedly false and/or misleading statements and/or failed to disclose to Aegerion Pharmaceuticals, Inc.investors that Aegerion Pharmaceuticals, Inc.marketed its drugs in violation of the FDCA, that as a result, Aegerion Pharmaceuticals, Inc.faced heightened regulatory scrutiny by the FDA and other governmental bodies, and that as a result of the foregoing, Aegerion Pharmaceuticals Inc’s statements were allegedly materially false and misleading at all relevant times.
On March 15, 2012, Aegerion Pharmaceuticals, Inc. filed its annual report with the SEC. On March 18, 2013, Aegerion Pharmaceuticals, Inc. filed its annual report with the SEC. Aegerion Pharmaceuticals, Inc.’s Net Loss increased from $12.20 million in 2009 to $62.27 million in 2012. Nevertheless, shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) grew from $12.04 per share in April 2012 to as high as $97.24 per share in October 2013.
Then in November 8, 2013, news reports revealed that Aegerion Pharmaceuticals, Inc. received an FDA Warning Letter (the, “Warning Letter”) in connection with statements the Company’s CEO made regarding JUXTAPID capsules, during broadcast interviews on CNBC’s television show, “Fast Money,” that aired on June 5, 2013, and October 31, 2013.
Then on January 9, 2014, Aegerion Pharmaceuticals, Inc. reported its preliminary 2013 Net
product sales, its outlook for 2014 and other business updates. Among other things, Aegerion Pharmaceuticals, Inc. announced that it has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney’s Office in Boston, MA, requesting documents regarding the Company’s marketing and sale of JUXTAPID in the U.S.
On May 27, 2016, NASDAQ:AEGR shares closed at $1.82 per share.
Those who purchased NASDAQ:AEGR shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego